Top Markets
Coin of the day
BELLUS Health Inc. BELLUS Health Inc.

BELLUS Health Inc.

BLU
Rangering i aksjer #6891
BELLUS Health Inc. is a biopharmaceutical firm in the clinical development... BELLUS Health Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to creating new therapeutic options for intractable chronic cough (RCC) and various other conditions characterized by heightened cough sensitivity. The company's primary investigational compound, BLU-5937, functions as a P2X3 receptor antagonist. This drug is currently progressing through Phase II clinical trials, where it is being assessed for its potential in treating both RCC and persistent itching. Founded in 1993, BELLUS Health Inc. is headquartered in Laval, Canada.
Aksjekurs
$14.30
Sist synkronisert: 2023-06-29
Markedsverdi
$1.81B
Endring (1 dag)
-2.81%
Endring (1 år)
0.00%
Land
CA
Handel BELLUS Health Inc. (BLU)

Kategori

P/S-forhold for BELLUS Health Inc. (BLU)
P/S-forhold per 2026 TTM: 0
Ifølge BELLUS Health Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for BELLUS Health Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
2.95 -
AU
11.28 -
US
- -
CH